Lyrica CR 82.5 mg/1 (Pregabalin TABLET, FILM COATED, EXTENDED RELEASE) 82.5 mg/1

Lyrica CR 82.5 mg is an extended-release formulation of pregabalin, used for managing certain types of nerve pain. This medication is designed to provide long-lasting relief and is commonly prescribed for neuropathic pain conditions.

Strength

82.5 mg/1

Pack Size

30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0071-1026-01)

Manufacturer / TM Owner

Parke-Davis Div of Pfizer Inc

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Lyrica CR 82.5 mg is primarily used for the management of neuropathic pain, which is often described as sharp, burning, or electric shock-like pain. This medication is designed to provide extended relief, making it suitable for conditions that require consistent pain management. Pregabalin, the active ingredient, is often used for what is pregabalin used for, including diabetic nerve pain and postherpetic neuralgia.

Side Effects

Common effects of Lyrica CR 82.5 mg may include dizziness, drowsiness, and peripheral edema. Some users might experience weight gain or blurred vision. These effects can vary from person to person and may subside as the body adjusts to the medication.

Precautions & Warnings

Lyrica CR 82.5 mg should be handled with care, especially for individuals with a history of heart or kidney issues. It is important to follow the prescribed dosage and avoid abrupt discontinuation. Always consult a healthcare provider before starting or stopping any medication.

Avoid Interactions

Lyrica CR 82.5 mg may interact with alcohol, leading to increased drowsiness. It can also interact with certain medications that affect the central nervous system, such as opioids or benzodiazepines. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.

Frequently Asked Questions

Lyrica CR 82.5 mg is used for managing neuropathic pain, including conditions like diabetic nerve pain and postherpetic neuralgia.

Lyrica CR 82.5 mg is taken orally, typically once daily, and should be swallowed whole with water. It is designed for extended release, so crushing or chewing the tablet is not recommended.

Common side effects may include dizziness, drowsiness, and peripheral edema. Some users might also experience weight gain or blurred vision.

It is generally advised to avoid alcohol while taking Lyrica CR 82.5 mg, as it can increase the risk of drowsiness and other side effects.

Lyrica CR 82.5 mg may not be suitable for everyone, especially those with a history of heart or kidney issues. Always consult a healthcare provider before starting this medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.